Present and future approaches to Parkinson disease: From molecular insights to new therapeutic avenues

Neurology

Volumn 67, Issue 7 SUPPL. 2, 2006, Pages

  Fariello, Ruggero G ^a   Lieberman, Abraham ^b  

^a BioNeuroFar   (Italy)

^b Lieberman Parkinson Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA SYNUCLEIN; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; BELLADONNA ALKALOID; DOPAMINE; LEVODOPA; MONOAMINE OXIDASE B INHIBITOR; MONOAMINE OXIDASE INHIBITOR; NEUROMELANIN; NORADRENALIN; UBIQUITIN;

ALZHEIMER DISEASE; BRAIN DEPTH STIMULATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; DOPAMINE METABOLISM; DYSKINESIA; EDITORIAL; GLOBUS PALLIDUS; HIPPOCAMPUS; HUMAN; HUNTINGTON CHOREA; LEWY BODY; NAUSEA; NEUROPROTECTION; NUCLEUS ACCUMBENS; OLIVARY NUCLEUS; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; SUBSTANTIA NIGRA; SYMPTOMATOLOGY; TREATMENT DURATION; VOMITING;

EID: 33750031717     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.67.7_suppl_2.s1     Document Type: Editorial

References (24)

1. Parkinson J. An essay on the shaking palsy. London: Sherwood, Neely, and Jones, 1817.
2. Brissaud E. Leçons sur les maladies nerveuses. Paris: Masson, 1895: 469-501.
3. Tretiakoff C. Contributions a l'étude de l'anatomie patholgique du locus niger de Soemmering avec quelques déductions relatives à la pathogénie des troubles de tonus musculaire et de la maladie de Parkinson. Paris. Thesis, 1919.
4. Foix C, Nicolesco J. Anatomie cérebrale: les noyaux gris centraux et la région mesenchephalo-soux-optique. Paris: Masson, 1925.
5. Hassler R. Zur Pathologie der Paralysis agitans und des postenzephalitischen Parkinsonismus. J Psychol Neurol 1938;48:387-476.
6. Hornykiewicz O. The discovery of dopamine deficiency in the parkinsonian brain. J Neural Transm Suppl 2006;70:1-7.
7. Montagu KA. Catechol compounds in rat tissues and in brains of different animals. Nature 1957;189:244-245.
8. Carlsson A, Lindqvist M, Magnusson T. 3,4 dihydroxyphenylalanine and 5-hydroxytryptamine as reserpine antagonists. Nature, 1957;180:1200-1205.
9. Ehringer H, Hornykiewicz O. Verteilung von Noradrenalin und Dopamin (3-Hydroxytyramin) im gehirn des Menschen und ihr Verhalten bei Erkrankungen des extrapyramidalen Systems. Wien Klin Wochenschr, 1960;38:1236-1239.
10. Hornykiewicz O. Die topische L̈okalisation und das Verhalten von Noradrenalin und Dopamin (3-Hydroxytyramin) in Substantia Nigra des normalen und Parkinsonkranken Menscehn. Wien Klein Wochenschr., 1963;75:309-312.
11. Hillarp NA, Fuxe K, Dahlstrom A. Demonstration and mapping of central neurons containing dopamine, noradrenaline, and 5-hydroxytryptamine and their reactions to psychopharmaca. Pharmacol Rev, 1966;18:727-741.
12. Birkmayer W, Hornykiewicz O. Der L-Dioxyphenylalanin (DOPA)-Effekt bei der Parkinson akinesie. Wien Klin Wochenschr, 1961;73:787-788.
13. Cotzias GC, Van Woert MH, Schiffer LM. Aromatic amino acids and modification of parkinsonism. N Engl J Med, 1967;276:374-379.
14. Lieberman A, Kupersmith M, Estey E, Goldstein M. Treatment of Parkinson's disease with bromocriptine. N Engl J Med, 1976;294:1400-1404.
15. Kebabian JW, Calne DB. Multiple receptors for dopamine. Nature, 1979;277:93-96.
16. Lieberman A, ed. Emerging perspectives in Parkinson disease Neurology, 1992;42 (suppl 4):S5-S7.
17. Lieberman A. Adrenal transplants revisited. Mayo Clin Proc, 1990;65:427-430, 1990. Editorial.
18. Lieberman A. Depression in Parkinson's disease: a review. Acta Neurol Scand, 2006;113:1-8.
19. Langston JW, Ballard P, Tetrud JW, Irwin I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science, 1983;219:979-980.
20. Langston JW, Forno LS, Rebert CS, Irwin I. Selective nigral toxicity after systemic administration of 1-methyl-4-phenyl-1,2,5,6-tetrahydropyrine (MPTP) in the squirrel monkey. Brain Res, 1984;292:390-394.
21. Poirier LJ, Sourkes TL. Influence of the substantia nigra on the catecholamine content of the striatum. Brain, 1965;88:181-192.
22. Gusella JF, Wexler NS, Conneally PM, et al. A polymorphic DNA marker genetically linked to Huntington's disease. Nature, 1983;306:234-238.
23. Polymeropoulos MH, Higgins JJ, Golbe LI, et al. Mapping of a gene for Parkinson's disease to chromosome 4. Science, 1996;274: 1197-1199.
24. Lieberman A, Dziatelowski M, Kupersmith M. Dementia in Parkinson. Ann Neurol, 1979;6:235-359.